Cti Biopharma reported $-19506000 in Operating Profit for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Applied Genetic Technologies AGTC:US $ -13.79M 0.7M
Baxter International BAX:US $ 424M 34M
Bristol Myers Squibb BMY:US $ 1715M 36M
Cti Biopharma CTIC:US $ -19.51M 2.44M
Cytori Therapeutics CYTX:US $ -2575000 96K
Eli Lilly And LLY:US $ 1403.4M 248.1M
Geron GERN:US $ -28.89M 0.44M
Mirati Therapeutics MRTX:US $ -164.19M 31.76M
Northwest Biotherapeutics NWBO:US -12543000 7.03M
Novartis NOVN:VX 3.48B 1.06B
Novartis NVS:US $ 3479M 1064M
Seattle Genetics SGEN:US $ -89.6M 32.82M
Sunesis Pharmaceuticals SNSS:US $ -9.06M 69.78M
Teva Pharmaceutical Industries TEVA:US $ 582M 148M
YTE INCY:US $ 140.84M 42.04M